Coronary Artery Bypass Grafting (CABG)
Conditions
Interventions
Intervention group:Innovatively designed, the HeartMed Digital Clinical Management System enables home-based monitoring of indicators such as body weight, heart rate, blood pressure, electrocardiogram
Control group:Regular outpatient follow-up
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 75 years old (inclusive), gender unrestricted; 2. Patients diagnosed with coronary heart disease (CHD) by imaging examinations who have undergone Coronary Artery Bypass Grafting (CABG); 3. Patients agree to comply with the study protocol and sign the informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1. Patients who have undergone emergency or rescue surgery; 2. Patients who undergo valvular surgery, major vascular surgery, or other concurrent surgeries; 3. Pregnant or lactating patients, or those planning to become pregnant within 1 year; 4. Patients who have undergone mechanical circulatory support (MCS) (such as intra-aortic balloon pump (IABP), Impella, extracorporeal membrane oxygenation (ECMO), or other MCS modalities) or endotracheal intubation; 5. Patients with a history of viral myocarditis or non-ischemic cardiomyopathies such as dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), peripartum cardiomyopathy (PPCM); 6. Patients with moderate to severe valvular heart disease (VHD) or a history of valve replacement; 7. Patients with severe liver dysfunction (alanine aminotransferase [ALT] >= 3 times the upper limit of normal [ULN]) or renal dysfunction (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m^2); 8. Patients with malignancies or other diseases who have a life expectancy of less than 1 year; 9. Patients who are unable to use smartphones for any reason or have difficulty communicating with the study management team; 10. Patients who are currently participating in other clinical trials; 11. Patients who, in the investigator’s judgment, have any other clinical conditions that are not suitable for enrollment in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of composite endpoint (including all-cause mortality, acute myocardial injury, sternotomy, stroke, arrhythmia, bleeding, infection, or acute kidney injury) at 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score (SF-36 questionnaire);Self-rating Anxiety Scale score;Self-rating Depression Scale score;Seattle Angina Questionnaire score; | — |
Countries
China
Contacts
Public ContactSong Yue
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed